UnitedHealth falls after report it secretly paid nursing homes to reduce hospital transfers

By Sriparna Roy

May 21, 2025 – 7:13 AM PDT

The corporate logo of the UnitedHealth Group appears on the side of one of their office buildings in Santa Ana, California, U.S., April 13, 2020. REUTERS/Mike Blake/File Photo
REUTERS/Mike Blake/File Photo

(Reuters) – UnitedHealth (UNH.N) shares fell more than 6% on Wednesday after the UK’s Guardian newspaper reported that the company made secret payments to nursing homes to reduce hospital transfers, adding to the woes of the healthcare conglomerate.

The alleged action, part of a series of cost-cutting tactics, has saved the company millions, but at times risked residents’ health, the Guardian reported, citing an investigation.

Advertisement

The allegations add to the litany of negatives that have hurt UnitedHealth in the last several months, following a massive cyberattack at its Change Healthcare unit, reports of criminal and civil investigations into the company’s practices, including one for Medicare fraud and the abrupt departure of CEO Andrew Witty last week.

Shares have stumbled all year, losing more than 39%, compared with a 0.6% decrease for the Dow.

UnitedHealth said in response that “the U.S. Department of Justice investigated these allegations, interviewed witnesses, and obtained thousands of documents that demonstrated the significant factual inaccuracies in the allegations.”

The company also said in an emailed statement that the DoJ declined to pursue the matter after reviewing all the evidence during its multi-year investigation.

Reuters has not independently verified the article’s allegations.

“The news is only seemingly getting worse for UnitedHealth,” said Sahak Manuelian, managing director, global equity trading at Wedbush.

“This is kind of a tough situation for investors to come in and have any kind of confidence in putting money to work, so we’ll have to kind of wait and see how this plays itself out, unfortunately,” Manuelian said.

Separately, HSBC downgraded the stock to “reduce” from “hold,” and cut the price target to a street-low of $270.

The brokerage said higher medical costs, pressure on drug pricing and its pharmacy benefit management unit, OptumRx, and a potential Medicaid funding cut can upset the company’s recovery journey.

The company is now counting on the experience of Stephen Hemsley, who returned as CEO to steer it through the current crisis.

“We believe Hemsley has the experience and leadership attributes that the company needs to restore credibility and right the ship,” said James Harlow, senior vice president at Novare Capital Management.

Reporting by Sriparna Roy in Bengaluru; Additional reporting by Twesha Dikshit in Bengaluru; Editing by Anil D’Silva

Share this post!